Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:09:03.171Z.
Consensus retrieved: 2026-10-06T14:48:30.434Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:09:03.171Z.
Quote observation: 2026-10-06T16:05:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d71c6897c98d436948f76d79272a6a7ae3c560285f8867db41996dc6a6301e16
FORWARD PE RATIO
N/A
Oncolytics Biotech Inc.
Market Cap
$59.65M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Oncolytics Biotech Inc. (ONCY) | $59.65M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $59.84M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.23M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.62M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $61.14M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.65M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.19M | N/A |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in CAD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
